Are there new combination strategies for treating tumors like Liver Cancer?
Liver cancer, particularly hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths worldwide 78. Treatment has evolved from single therapies to combination strategies that target multiple pathways. For advanced HCC, systemic therapies now combine immune checkpoint inhibitors with anti-angiogenic drugs 7. For surgical candidates, techniques like hepatic vein occlusion combined with portal vein embolization are improving the safety and feasibility of major liver resections 2. These approaches aim to improve survival and quality of life.
What the research says
A 2025 review highlights that advanced HCC is now treated with systemic therapies, including anti-angiogenic agents and immune checkpoint inhibitors, which are often used in combination 7. This represents a shift from earlier years when sorafenib was the only effective systemic therapy for advanced HCC 8. The review also notes that MASH-related HCC has distinct molecular and immune characteristics, which may influence treatment response 7.
For patients needing surgery, a meta-analysis of 103 studies found that combining hepatic vein occlusion with portal vein embolization increased the future liver remnant by 36.8%, which is 24.5% greater than portal vein embolization alone 2. This technique may allow more patients to safely undergo curative resection 2.
Other combination strategies under investigation include immunochemotherapy, oncolytic viruses, targeting cancer stem cells, epigenetic modulation, and nanoparticle-based drug delivery systems, as reviewed for digestive system tumors including liver cancer 5. These are largely experimental but show promise in overcoming chemotherapy resistance 5.
Additionally, biomarkers are playing a growing role in guiding targeted therapy. For liver cancer, alpha-fetoprotein remains a classic marker, but newer genomic markers are emerging that may help personalize combination treatments 4.
What to ask your doctor
- What combination therapy is recommended for my specific stage and type of liver cancer?
- Are there any clinical trials testing new combination strategies that I might be eligible for?
- How might my liver function and overall health affect my ability to tolerate combination treatments?
- What are the potential side effects of combining immunotherapy with anti-angiogenic drugs?
- If surgery is an option, could techniques like hepatic vein occlusion with portal vein embolization improve my chances of a successful resection?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.